All News

A sign of the times or a rash decision? In an effort to curb unnecessary costs, Pfizer kills development of two late-stage products rather than sink more money into them.

Reflector welcomes the signs of EU agreement on encouraging the development of rare disease treatments.

Two pharma companies dabble in online video in two different but effective ways. Sanofi-aventis attempts to reach patients through educational videos, while AZ calls for consumers to upload their own testimonials.

The hunt is on. Generic drug companies must find executives with the requisite capabilities for managing a global yet highly local business, and that can maintain the entrepreneurial culture on which their competitive advantage depends.

Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year.

GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts.

Reflector wonders whether the UK government's business supremo can work his magic on European pharma and biotech.

Though they are made up of similar genetic material, siblings are very different people. Michael Jackson is different from La Toya Jackson. Julia Roberts is different from Eric Roberts. They share many characteristics, but they certainly are not the same.

Communications planning in 2009 and beyond will include online, offline, mobile, out-of-home, point-of-sale, gaming consoles, and more-even your car's navigation system will be tied to Google! Perhaps most importantly, communications planning will begin to include social influence marketing.

Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.

Pfizer switched agencies for its popular smoking cessation drug Chantix. While the company is tight lipped about the campaign's new direction, it looks like this may be the end of the tortoise and hare. Does this signal an end to the use of critters in pharma ads?

June 2008 Sworn Statement

No one who cares about global health can be happy with a system that only "eventually" delivers drugs and vaccines for the planet's neediest people

The pharma industry has come a long way since Hurricane Katrina when it comes to disaster planning. Now, with experts predicting an influenza pandemic, companies have a chance to prepare systems before a crisis happens.

Big name patent expirations may be looming, but that's not stopping pharma companies from filing - and getting approved for - dozens of new patents. Pharm Exec looks at which companies are getting the most approvals, and how 2008 compared to previous years.

Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough to get the biotech's board of directors to sign on the dotted line.

Pfizer hit hard with the surprise purchase of Wyeth. But will the pharma giant strike out in the long run? Analysts ponder the long and short-term ramifications of this monster acquisition.

As pharmaceutical companies look to emerging markets to offset slowed growth at home, success will depend on efficient re-use of regulatory content to target new high-growth markets.

To increase impact and effectiveness, personalized Web sites should be constructed in different ways to interact with multiple audiences.

A new study suggests the medical professionals are more active on social networking sites than ever before. With the rise of doctor-specific Web 2.0 outlets, pharma has a new tool for reaching elusive physicians. The best part: Doctors don?t seem to mind.

Reflector casts doubt on European pharma's vision for further communication between the industry and its patients.

Economic Development promo sheet 2

Economic Development Sample

Although stem cell research has sparked controversy for years, Osiris Therapeutics has been flying under the radar for a decade with a revolutionary secret.

The Tamiflu-resistant flu strain means increased sales for GSK's Relenza, but doesn't mean the end for the number-one antiviral.

Sales reps aren't the only ones heading for the unemployment line - Pfizer is eliminating researcher positions as fewer drugs are making it to development. But could streamlining the crux of drug R&D cause more harm than good?

Merck isn't bragging about the positive data it received regarding the use of its landmark HPV vaccine in men. But the pharma giant also isn't wasting time submitting the info to FDA. Pharm Exec talked to the lead investigator behind the trials to find out why this could be another milestone for Merck.

One week into the new year, and word is trickling out that some large advertising firms are gearing up for heavy cuts. First out the gate is WPP, which is expected to be cutting thousands of jobs.

With the departure and retirement of two-thirds of Donahoe Purohit Miller, the middle child has rebranded itself Purohit Navigation and is going after the pharma market as a one-stop-shop for all its branding needs.

HBA Endorsement letter